Changes in Beneficial Ownership · 4
Insight Molecular Diagnostics Inc.
IMDXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-17
- Issuer
- Insight Molecular Diagnostics Inc.
- Issuer CIK
- 0001642380
- Trading symbol
- IMDX
Reporting owner 1
- Name
- BROADWOOD PARTNERS, L.P.
- Reporting owner CIK
- 0001278386
- Relationship
- 10% owner
- Address
- C/O BROADWOOD CAPITAL INC, 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK, NY, 10019
Reporting owner 2
- Name
- BROADWOOD CAPITAL INC
- Reporting owner CIK
- 0001278387
- Relationship
- 10% owner
- Address
- 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK, NY, 10019
Reporting owner 3
- Name
- Bradsher Neal C
- Reporting owner CIK
- 0001278388
- Relationship
- 10% owner
- Address
- C/O BROADWOOD CAPITAL INC, 156 WEST 56TH STREET, 3RD FLOOR, NEW YORK, NY, 10019
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par value | 2026-11-17 | P · Form 4 | 3,428,571 | A | 1.75[F3] | 16,113,455 | D[F1] | |
| Common Stock, no par value | 2026-11-17 | P · Form 4 | 0 | A | 0 | 16,113,455 | I | Footnote[F1] |
Table key
- P · Form 4
- Purchase on the market or privately
- A
- Acquired
- D
- Direct
- I
- Indirect
Non-derivative holdings
| Security | Amount owned | Ownership |
|---|---|---|
| Common Stock, no par value | 157 | D[F2] |
Table key
- D
- Direct
Derivative holdings
| Security | Conversion / exercise price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Warrant to Purchase Common Stock | 30.60 | [F4] | 2027-04-19 | Common Stock | 150,093 | 150,093 | D[F1] | |
| Warrant to Purchase Common Stock | 30.60 | [F4] | 2027-04-19 | Common Stock | 150,093 | 150,093 | I | Footnote[F1] |
Table key
- D
- Direct
- I
- Indirect
Footnotes
- F1
- The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.↩ 1↩ 2↩ 3↩ 4
- F2
- These securities are directly owned by Neal C. Bradsher.↩ 1
- F3
- On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share.↩ 1
Signature 1
- Signed
- Broadwood Partners, L.P., By: Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President
- Date
- 2026-11-19
Signature 2
- Signed
- Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President
- Date
- 2026-11-19
Signature 3
- Signed
- Neal C. Bradsher, /s/ Neal C. Bradsher
- Date
- 2026-11-19